Tg Therapeutics (TGTX) Non-Current Deffered Revenue (2012 - 2026)
Tg Therapeutics (TGTX) recorded quarterly Non-Current Deffered Revenue of $6.9 million in Q1 2026, down 22.07% quarter-over-quarter from $8.8 million in Q4 2025, and up 4.02% on a YoY basis from $6.6 million in Q1 2025.
Tg Therapeutics (TGTX) Non-Current Deffered Revenue (2012 - 2026) Analysis & Trends
Tg Therapeutics' Non-Current Deffered Revenue history runs 15 years deep, the most recent figure standing at $6.9 million for Q1 2026.
- In Q1 2026, Non-Current Deffered Revenue rose 4.02% year-over-year to $6.9 million; the TTM figure through Mar 2026 stood at $6.9 million (up 4.02% YoY), while the FY2025 annual figure was $8.8 million, down 27.12% from the prior year.
- Non-Current Deffered Revenue was $6.9 million for Q1 2026 at Tg Therapeutics, down from $8.8 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $16.2 million in Q3 2024 to a low of $190000.0 in Q3 2023.
- Historically, Non-Current Deffered Revenue has averaged $4.5 million across 5 years, with a median of $3.2 million in 2024.
- The sharpest annual moves came in 2024 and 2025: Non-Current Deffered Revenue surged 8408.42% in 2024, then slumped 55.46% in 2025.
- A 5-year view of Non-Current Deffered Revenue shows it stood at $305000.0 in 2022, then soared by 1872.46% to $6.0 million in 2023, then surged by 100.88% to $12.1 million in 2024, then declined by 27.12% to $8.8 million in 2025, then decreased by 22.07% to $6.9 million in 2026.
- The last three Non-Current Deffered Revenue figures came in at $6.9 million (Q1 2026), $8.8 million (Q4 2025), and $8.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Tg Therapeutics | 7.71 Bn | 7.06 Bn | 171.41 Mn | 6.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.86 Mn |
| Dec 31, 2025 | 8.81 Mn |
| Sep 30, 2025 | 8.35 Mn |
| Jun 30, 2025 | 1.67 Mn |
| Mar 31, 2025 | 6.60 Mn |
| Dec 31, 2024 | 12.09 Mn |
| Sep 30, 2024 | 16.17 Mn |
| Jun 30, 2024 | 3.74 Mn |
| Mar 31, 2024 | 3.24 Mn |
| Dec 31, 2023 | 6.02 Mn |
| Sep 30, 2023 | 190,000.00 |
| Jun 30, 2023 | 229,000.00 |
| Mar 31, 2023 | 267,000.00 |
| Dec 31, 2022 | 305,000.00 |
| Sep 30, 2022 | 343,000.00 |
| Jun 30, 2022 | 381,000.00 |
| Mar 31, 2022 | 419,000.00 |
| Dec 31, 2021 | 457,000.00 |
| Sep 30, 2021 | 495,000.00 |
| Jun 30, 2021 | 533,000.00 |